Resolve Medical launches AI deprescribing tool for medication review workflows

Resolve Medical has launched IntractMD Deprescribing Intelligence, an AI-assisted clinical decision-support capability for pharmacists, MTM programs and care teams. The tool is designed to model hypothetical medication-removal scenarios, rank potential deprescribing candidates and support clinical documentation without replacing professional judgment.

Why it matters: - Medication safety and polypharmacy remain a major focus for Medicare organizations, health plans, clinical pharmacy programs and care-management teams. - Resolve Medical is targeting a workflow gap: helping teams move from identifying medication risk to documenting and reviewing potential deprescribing options more systematically. - The platform is designed to support, not replace, pharmacist and prescriber judgment.

What happened: - Resolve Medical announced the availability of IntractMD Deprescribing Intelligence, an AI-assisted clinical decision-support capability. - The launch was announced Sept. 8, 2026, from Cleveland. - The capability is designed for pharmacists, medication therapy management programs and care teams evaluating medication risks and deprescribing scenarios. - Resolve Medical is offering qualified organizations a no-cost 60-day evaluation of IntractMD. - More information is available at the company's announcement.

The details: - IntractMD is built to complement existing medication-management workflows, especially for polypharmacy patients with complex regimens. - The platform uses an N+1 counterfactual approach to model hypothetical medication-removal scenarios one medication at a time. - It recalculates the Composite Polypharmacy Risk Score across eight clinical dimensions for each scenario. - The system uses published deprescribing criteria from AGS Beers, STOPP/START and CMS Star Ratings measures. - IntractMD ranks scenarios to help care teams identify medications that may warrant further clinical review. - The platform provides before-and-after CPRS comparisons, structured clinical briefings, supporting evidence citations and PDF export for documentation and communication. - Clinical MTM Workflow can generate patient outreach communications in English or Spanish, including email, SMS and call scripts. - The pilot offering includes a patient-facing drug Interaction Checker, a Proactive Supplement & Food Screening Engine, Clinical MTM Workflow and Deprescribing Intelligence. - No EHR integration is required to begin a pilot. - The program is intended for health plans, pharmacy organizations, MTM programs and hospital or health-system clinical pharmacy teams.

Between the lines: - The launch reflects growing pressure on healthcare organizations to make medication review, quality-measure reporting and deprescribing work more structured. - Resolve Medical is positioning IntractMD as a workflow support tool that can help teams document reasoning and organize follow-up, not as an automated prescribing replacement. - The product also expands beyond prescription drugs to include supplements and food screening, signaling a broader medication-risk lens. - Tom Lash, founder and CEO of Resolve Medical, said the patent-pending feature is meant to make it easier to identify where to begin and to document clinical reasoning.

What's next: - Qualified organizations can begin a 60-day pilot without EHR integration. - Resolve Medical is pitching the platform to health plans, pharmacy organizations, MTM programs and clinical pharmacy teams that want to test new medication-risk workflows. - The company says IntractMD will continue to be positioned as a clinical decision-support tool rather than a substitute for professional medical advice or independent clinical judgment.

The bottom line: - Resolve Medical is betting that AI can make deprescribing review faster, more structured and easier to document without taking clinical control away from pharmacists and care teams.